Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Sobetirome (GC-1) is a non-peptide small-molecule thyromimetic that selectively activates thyroid hormone receptor beta (TRβ) over TRα, designed to lower cholesterol and triglycerides without the cardiac effects of natural thyroid hormone. It completed Phase 1 trials in healthy volunteers for dyslipidemia (discontinued), but has no FDA or EMA approval and no validated human dose for any indication. Planned human trials in X-linked adrenoleukodystrophy were withdrawn before enrollment; all neurological data are preclinical only.
0 of 1 vendors lab-verified
Verified purity per dollar — the cheapest that's actually been tested
No prices found for Sobetirome (GC-1).
Single-vial list prices by default for a fair head-to-head — switch to Multi-vial / bulk for pack pricing. Estimates only; verify at vendor before purchase. For research use only. Not medical advice.
Kimera Chems has the lowest single-vial Sobetirome (GC-1) price at $13.33/mg among 1 COA-verified vendor on Disclosed Labs. Bulk or multi-vial deals may be lower.
What is the price range for Sobetirome (GC-1)?
Research-grade Sobetirome (GC-1) is listed at $13.33/mg from 1 verified source on Disclosed Labs.
How are Sobetirome (GC-1) prices verified on Disclosed Labs?
Every listed vendor holds a Grade C or better trust score, computed independently from lab Certificates of Analysis — not from payments or sponsorships. Prices are scraped and fact-checked daily. Vendors cannot pay to improve their ranking.
Check formulation: Lyophilized powder requires reconstitution before use. Pre-mixed solutions are more convenient but may have a shorter shelf life and higher prices.
Compare per-mg cost: Different strengths and quantities make direct price comparison difficult. Calculate the per-milligram cost to find the true best value.
Verify COAs: Look for vendors that publish per-batch Certificates of Analysis from named, accredited labs. Use the Full safety panel filter to require endotoxin, sterility, and heavy-metals testing on the current batch — not just HPLC purity.
Human data are limited to Phase 1 trials in healthy volunteers conducted by QuatRx Pharmaceuticals; company press releases (not peer-reviewed) reported LDL-C reductions up to 22% (single-ascending-dose, 1–450 mcg) and 41% (multiple-ascending-dose, 10–100 mcg/day × 14 days) with no significant heart-rate or TSH change. Development for dyslipidemia was discontinued and no Phase 2/3 data exist. Two planned human trials in X-linked adrenoleukodystrophy (NCT01787578, NCT03196765) were withdrawn before enrolling any participants; zero human neurological efficacy data exist. In Abcd1 knockout mice (X-ALD model), intraperitoneal dosing (0.1–1.0 mg/kg/day, 7–28 days) lowered serum and tissue very-long-chain fatty acid (VLCFA) levels; chronic oral dosing (0.4–2.0 mg/kg, 11–18 weeks) modestly reduced brain C26 VLCFA by 13–24% after 12 weeks, though the higher dose caused up to 20% body-weight loss requiring early termination. In experimental autoimmune encephalomyelitis mice, sobetirome reduced clinical disease severity, axonal degeneration, and oligodendrocyte loss versus vehicle controls.
This platform provides informational tools only, not medical advice.
Prices verified as of July 2026. Actual prices may vary. For research use only.
Disclosed Labs